Stayble Therapeutics AB engages in the development of pharmaceutical products. It develops an injectable treatment against chronic low back pain triggered by disc degeneration. The company was founded by Kjell Olmarker, Mattias Münnich, and Andreas Gerward in 2015 and is headquartered in Gothenburg, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company